OVID
Price
$0.31
Change
-$0.00 (-0.00%)
Updated
Apr 1 closing price
Capitalization
22.14M
36 days until earnings call
TVTX
Price
$17.43
Change
-$0.49 (-2.73%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
1.55B
29 days until earnings call
Ad is loading...

OVID vs TVTX

Header iconOVID vs TVTX Comparison
Open Charts OVID vs TVTXBanner chart's image
Ovid Therapeutics
Price$0.31
Change-$0.00 (-0.00%)
Volume$339.34K
Capitalization22.14M
Travere Therapeutics
Price$17.43
Change-$0.49 (-2.73%)
Volume$51.81K
Capitalization1.55B
OVID vs TVTX Comparison Chart
Loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TVTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OVID vs. TVTX commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a StrongBuy and TVTX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (OVID: $0.31 vs. TVTX: $17.92)
Brand notoriety: OVID and TVTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OVID: 589% vs. TVTX: 147%
Market capitalization -- OVID: $22.14M vs. TVTX: $1.55B
OVID [@Biotechnology] is valued at $22.14M. TVTX’s [@Biotechnology] market capitalization is $1.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OVID’s FA Score shows that 1 FA rating(s) are green whileTVTX’s FA Score has 0 green FA rating(s).

  • OVID’s FA Score: 1 green, 4 red.
  • TVTX’s FA Score: 0 green, 5 red.
According to our system of comparison, TVTX is a better buy in the long-term than OVID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OVID’s TA Score shows that 3 TA indicator(s) are bullish while TVTX’s TA Score has 4 bullish TA indicator(s).

  • OVID’s TA Score: 3 bullish, 3 bearish.
  • TVTX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, OVID is a better buy in the short-term than TVTX.

Price Growth

OVID (@Biotechnology) experienced а -29.80% price change this week, while TVTX (@Biotechnology) price change was -15.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.07%. For the same industry, the average monthly price growth was -13.26%, and the average quarterly price growth was -12.25%.

Reported Earning Dates

OVID is expected to report earnings on May 08, 2025.

TVTX is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-9.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TVTX($1.55B) has a higher market cap than OVID($22.1M). TVTX YTD gains are higher at: 2.870 vs. OVID (-66.595). OVID has higher annual earnings (EBITDA): -61.27M vs. TVTX (-265.77M). TVTX has more cash in the bank: 371M vs. OVID (53.1M). OVID has less debt than TVTX: OVID (14.8M) vs TVTX (402M). TVTX has higher revenues than OVID: TVTX (233M) vs OVID (566K).
OVIDTVTXOVID / TVTX
Capitalization22.1M1.55B1%
EBITDA-61.27M-265.77M23%
Gain YTD-66.5952.870-2,320%
P/E RatioN/AN/A-
Revenue566K233M0%
Total Cash53.1M371M14%
Total Debt14.8M402M4%
FUNDAMENTALS RATINGS
OVID vs TVTX: Fundamental Ratings
OVID
TVTX
OUTLOOK RATING
1..100
5255
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
86
Overvalued
PROFIT vs RISK RATING
1..100
10089
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9737
P/E GROWTH RATING
1..100
9339
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (31) in the Pharmaceuticals Major industry is somewhat better than the same rating for TVTX (86) in the Biotechnology industry. This means that OVID’s stock grew somewhat faster than TVTX’s over the last 12 months.

TVTX's Profit vs Risk Rating (89) in the Biotechnology industry is in the same range as OVID (100) in the Pharmaceuticals Major industry. This means that TVTX’s stock grew similarly to OVID’s over the last 12 months.

OVID's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as TVTX (100) in the Biotechnology industry. This means that OVID’s stock grew similarly to TVTX’s over the last 12 months.

TVTX's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for OVID (97) in the Pharmaceuticals Major industry. This means that TVTX’s stock grew somewhat faster than OVID’s over the last 12 months.

TVTX's P/E Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for OVID (93) in the Pharmaceuticals Major industry. This means that TVTX’s stock grew somewhat faster than OVID’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OVIDTVTX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 21 days ago
76%
Bullish Trend 13 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
View a ticker or compare two or three
Ad is loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TVTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EIUTX15.66N/A
N/A
Eaton Vance Dividend Builder I
JDBRX44.11N/A
N/A
Janus Henderson Balanced R
ATGYX40.10N/A
N/A
Cantor Fitzgerald Equity Opp Inst
DMCRX11.59N/A
N/A
Driehaus Micro Cap Growth
GAOZX20.23-0.01
-0.03%
JPMorgan Global Allocation R6